Post-earnings recap
Reported
Thu, May 7, 2026
EPS actual
$0.13
EPS est.
$0.12
EPS surprise
+5.94%
1-day move
-5.11%
Stevanato Group reported better-than-expected earnings per share, but did not provide revenue figures. The stock reacted negatively, dropping 5.1%, which may indicate investor concerns despite the EPS beat. The lack of guidance and revenue information could have contributed to the stock's decline.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.13 | $0.12 | +5.44% |
| Revenue | N/A | $269M | N/A |
No transcript is on record, and the analysis is based solely on numerical results.
Stevanato Group S.p.A. is a healthcare company that specializes in life sciences tools and services, particularly focusing on the production of glass vials and other packaging solutions for the pharmaceutical industry. As a key player in the healthcare sector, the company is positioned to benefit from ongoing trends in drug development and increased demand for safe and effective drug delivery systems.
Last quarter
In Q4 2025, Stevanato reported earnings of $0.20 per share, matching analyst expectations, and the stock rose by 18.81% the following day. The company has shown a consistent ability to meet or exceed earnings expectations in recent quarters.
EPS beat streak
2Q
EPS beat rate
75%
Avg EPS surprise
+6.58%
Avg 1-day reaction
+3.11%
Analysts expect Stevanato to report earnings of $0.12 per share and revenue of $269 million for Q1 2026, reflecting stable performance amid a challenging market. Investors will be keen to see if the company can maintain its growth trajectory.
Bull case
If Stevanato exceeds earnings expectations and demonstrates strong revenue growth, it could signal robust demand for its products, potentially leading to a significant stock price increase.
Bear case
Conversely, if the company misses earnings or revenue targets, it may raise concerns about its market position and future growth prospects, leading to a negative reaction in the stock.
Key metrics to watch
EPS
$0.12Earnings per share is a crucial indicator of the company's profitability and financial health, which investors closely monitor.
Revenue
$269MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will EPS exceed the consensus estimate of $0.12?
A beat on EPS would reinforce investor confidence in the company's profitability and growth potential.
Q2
What is the revenue outlook compared to the consensus of $269 million?
Revenue performance will be critical in assessing demand for Stevanato's products and overall market health.
—
Est. EPS
$0.14
Est. Rev
$2.4B
Impl. Move
±9.5%
Why consensus could be wrong
While consensus expects stable earnings, the market may be underestimating the potential for Stevanato to capitalize on increased demand for drug delivery systems, particularly in emerging markets.
Supporting evidence
The company's recent performance has shown a consistent ability to exceed expectations, suggesting potential for continued growth.
Options pricing reflects a significant expected move, indicating that traders anticipate volatility that may not be fully captured by consensus estimates.
Key risk
If revenue growth exceeds $269 million, it could challenge the current bearish sentiment and shift investor outlook positively.
Pre-commit to what would confirm each case.
The market is debating whether Stevanato can sustain its growth amid competitive pressures and changing market dynamics.
Bull confirmed if
Earnings exceeding $0.12 with revenue above $269 million would confirm the bull case.
Bear confirmed if
Earnings below $0.11 or revenue falling short of $267 million would confirm the bear case.
What the market is pricing for the move.
Implied Move
±42.28%
Historical Avg
±8.5%
The options market is pricing in a significant move for Stevanato's stock, indicating that traders expect a high level of volatility around the earnings report.
Options are pricing ±7.0% while STVN has averaged ±8.5% over the last 8 prints — setup is pricing cheap.
ATM IV
0.8%
30d HV
37.6%
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$293,453.50
13,649 sh
1 insider
Net
$293,453.50
Net selling
Most Active Insiders· 1 open-market trade
$293,453.50
Net selling
Smart-money positioning from the most recent 13F filings.
Institutional
98.68%
of float
Insider
1.80%
of float
Holders
166
institutions
Top Holders· as of Jun 2026
Conestoga Capital Advisors, LLC
7,007,613 sh · $136.2M
2.31%
-17.5%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Stevanato beats expectations, history suggests the stock could rise around 3.1% on the next trading day, confirming strong demand and operational efficiency.
In line / cautious
If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance on future growth.
Miss
Should the company miss expectations, history indicates a potential decline of around 4.77%, raising concerns about its market position.
The lines on the call that would change the story.
Recent Transactions
Sep 28, 2026 · @ $21.50
13,649 sh
$293,453.50
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Neuberger Berman Group, LLC
5,622,269 sh · $109.3M
1.86%
25.6%
Times Square Capital Management, LLC
3,474,641 sh · $67.5M
1.15%
-0.4%
Van Berkom & Associates Inc.
2,969,220 sh · $57.7M
0.98%
1636.5%
Artisan Partners Limited Partnership
2,601,598 sh · $50.6M
0.86%
13.6%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.